TPG Capital has initiated an exclusive sale process for Lyric, a healthcare software platform, with early-stage indications pointing to a $5 billion valuation. The process is being run quietly, with outreach limited to strategic acquirers and larger buyout funds capable of writing nine-figure equity checks. TPG declined comment through a spokesperson.

Lyric operates revenue cycle management and clinical workflow software for mid-market healthcare providers, a segment that attracted heavy private equity interest between 2020 and 2022 when pandemic tailwinds and digitization mandates drove aggressive SaaS multiples. TPG acquired the asset in a structured carve-out from a larger healthcare IT roll-up in early 2021, paying an undisclosed amount rumored at the time to be in the $2.8 billion range. The firm has since executed three bolt-on acquisitions, adding patient engagement and telehealth modules to the core platform. Lyric now serves approximately 1,200 hospital systems and ambulatory care centers across 38 states, generating an estimated $420 million in annual recurring revenue with EBITDA margins in the mid-30s, according to two sources familiar with the financials.

The timing matters. Vertical software valuations have contracted sharply since mid-2022, with public comps like Veeva and MEDITECH trading at 8x to 11x forward revenue—down from 18x to 22x at peak. Private market exit multiples have followed, and TPG is now testing whether scarcity value in profitable, scaled healthcare IT assets can command a premium to the public benchmark. A $5 billion exit would imply roughly 12x trailing revenue, a meaningful step-up from the entry basis and a signal that TPG believes strategic buyers—particularly larger public software platforms or well-capitalized PE firms with healthcare mandates—will pay for durable, high-margin subscription revenue in a sector with regulatory tailwinds. The alternative is a longer hold, which exposes TPG to rising interest expense on the asset's $1.8 billion term loan and increasing LP pressure for distributions as fund vintages age.

Strategic acquirers with balance sheet capacity include Oracle Health, Epic Systems' private equity-backed competitors, and Optum's technology arm, all of which have expressed interest in expanding addressable market through adjacencies. On the financial sponsor side, firms like Thoma Bravo, Vista Equity, and Hellman & Friedman have raised healthcare-focused continuation vehicles in the past 18 months and could justify a platform bet at this scale. The process is expected to surface binding indications by late Q2, with a transaction close targeted for Q3 if momentum holds. TPG's exit decision will likely influence pricing expectations for two other large healthcare IT carve-outs rumored to be in preparation: a $3.2 billion patient data analytics platform held by KKR and a $4.1 billion population health management suite owned by Silver Lake.

Watch for disclosure of revenue growth rates and customer concentration. If Lyric is growing net revenue retention above 110% and no single customer represents more than 4% of ARR, the asset will command premium interest. If growth has decelerated below 15% year-over-year or churn has ticked above 6% annually, TPG may face a narrower buyer set and pressure to accept a lower multiple. The formal process is expected to run through mid-May, with data room access granted to qualified parties in the next three weeks.